June 15, 2020 / 12:18 PM / 24 days ago

BRIEF-Amarin Says Vascepa Shows Significant Cardiovascular Risk Reduction In People With Diabetes

June 15 (Reuters) - Amarin Corporation PLC:

* VASCEPA® (ICOSAPENT ETHYL) SHOWS SIGNIFICANT CARDIOVASCULAR RISK REDUCTION IN PEOPLE WITH DIABETES IN PRESPECIFIED AND POST HOC SUBGROUP ANALYSES OF LANDMARK REDUCE-IT® STUDY

* AMARIN CORPORATION PLC - KEY SECONDARY COMPOSITE FIRST AND TOTAL MACE REDUCTIONS OF 30% AND 29%, RESPECTIVELY

* AMARIN CORPORATION PLC - REDUCTIONS ALSO OBSERVED IN POST HOC EXPLORATORY ANALYSES OF OTHER COMPOSITE ENDPOINTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below